Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 11,267B 68.84B 60.52B 56.33B 51.74B 97.15B 6,602B 98.43B 670B 262B 3,260B 258B 253B P/E 2026 *
22.2x
P/E 2027 * 19x
Enterprise Value 10,263B 62.71B 55.12B 51.31B 47.12B 88.49B 6,013B 89.66B 610B 238B 2,969B 235B 230B EV / Sales 2026 *
7.39x
EV / Sales 2027 * 6.59x
Free-Float
38.12%
Yield 2026 *
1.99%
Yield 2027 * 2.3%
1 day+2.21%
1 week-5.38%
Current month-7.10%
1 month-7.59%
3 months-11.85%
6 months-17.14%
Current year-15.09%
1 week 6,795
Extreme 6795
7,509
1 month 6,795
Extreme 6795
7,939
Current year 6,795
Extreme 6795
10,700
1 year 5,942
Extreme 5942
10,700
3 years 4,076
Extreme 4076
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.3333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
+2.21%-5.38%-5.79%+69.63% 68.84B
+0.13%+4.41%+47.35%+163.20% 1,068B
+0.97%+6.88%+58.02%+53.12% 641B
-0.94%+1.39%+35.02%+72.60% 454B
+0.03%+7.79%+38.07%+33.56% 351B
+0.02%+2.07%+37.28%+41.98% 299B
-1.32%+1.36%+17.34%+14.50% 266B
+0.45%+0.88%-27.54%-38.13% 220B
+0.06%+3.32%+22.73%+59.40% 203B
+0.94%-2.02%+12.32%+70.59% 162B
Average +0.24%+1.83%+23.48%+54.04% 373.22B
Weighted average by Cap. +0.10%+2.68%+35.62%+77.53%

Financials

2026 *2027 *
Net sales 1,389B 8.49B 7.46B 6.95B 6.38B 11.98B 814B 12.14B 82.58B 32.25B 402B 31.87B 31.18B 1,539B 9.4B 8.27B 7.69B 7.07B 13.27B 902B 13.44B 91.45B 35.72B 445B 35.29B 34.53B
Net income 507B 3.1B 2.73B 2.54B 2.33B 4.37B 297B 4.43B 30.15B 11.78B 147B 11.64B 11.39B 592B 3.62B 3.18B 2.96B 2.72B 5.11B 347B 5.17B 35.2B 13.75B 171B 13.59B 13.29B
Net Debt -1,004B -6.14B -5.39B -5.02B -4.61B -8.66B -588B -8.77B -59.68B -23.31B -291B -23.03B -22.53B -1,120B -6.84B -6.01B -5.6B -5.14B -9.66B -656B -9.78B -66.55B -25.99B -324B -25.68B -25.13B
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,104
Date Price Change Volume
28/07/26 ¥6,999.00 +2.21% 4,135,500
27/07/26 ¥6,848.00 -7.66% 6,311,000
24/07/26 ¥7,416.00 +2.83% 2,827,400
23/07/26 ¥7,212.00 -1.29% 2,609,800
22/07/26 ¥7,306.00 -1.23% 2,064,700
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,848.00JPY
Average target price
9,686.67JPY
Spread / Average Target
+41.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4519 Stock